Global Next Generation Cancer Diagnostics Market by Technology (LOAC & RT-PCR, NGS), by Application (Biomarker, CTC), by Cancer Type (Breast, Lung) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028
Industry Insights
In 2015, the global market for next-generation cancer diagnostics was valued at more than USD 4.38 billion. This market is expected to grow significantly over the forecast period. The demand for next-generation tests for diagnosing cancer is expected to rise due to the rising incidence of oncology disorders. These tests will enable early diagnosis and efficient prognosis for various types of cancer. This is expected to positively impact the vertical's progress over the forecast period.
This market is expected to see lucrative growth opportunities due to the introduction and development of new product offerings by large companies. The market will see potential high-value opportunities and growth opportunities over the forecast period, thanks to the acceleration of the development and implementation of companion diagnostics in the delivery personalized and advanced genomic medicine.
Market share of the U.S. Next-Generation Cancer Diagnostics Market, by Technology Type, 2013-2024
The projected sector's progress is supported by active participation from global organizations such as the National Cancer Institute and the National Foundation for Cancer Research.
The forecast period will see continued advancements in diagnostic laboratories and the adoption of automated and integrated lab systems. This will increase the demand for workflow systems and revenue generation.
Market expansion will also be supported by the transition from traditional laboratory testing towards rapid point-of care testing. This is due to the expected commercialization and distribution of the technologically advanced products, including instruments and diagnostic kits.
Technology Insights
This study analyzed key technologies such as DNA microarrays and protein microarrays. These advantages include detection of gene duplications and deletions, melting curve analysis to identify mutations, and qPCR technology to profile tumors in clinical labs.
Comparable to traditional methods of testing, PCR-based methods are more cost-effective. This is a major driver for this market.
As a result, DNA and protein microarrays will see a decrease in usage. This technology is becoming more popular due to technological advances in NGS systems, the development of data interpretation tools and support protocols for library preparation. According to certain market analysts, DNA microarrays will lose a significant part of their market share to NGS diagnostics in the next decade.
Application Insights
Biomarker testing has shown high accuracy levels of up to 90% in research studies, and enhanced sensitivity for tumor screening. This segment is expected to experience significant growth over the next few years.
The forecast period will see a rise in the number of research projects that aim to develop innovative tools and solutions that enable early detection of cancer-causing mutations. This is expected to have a significant impact on the growth of genetic analysis for Oncology Diagnostics.
Cancer Types Information
The cancer types can be classified according to the location of the tumor. Other cancer types include leukemia, bladder and brain, skin, uterine Non-Hodgkin lymphoma (esophageal), liver, ovarian and prostate, as well as other cancers.
Because of the higher number of patent applications and research projects filed in this area, lung cancer was ranked second in terms of revenue generation in 2015. Lung cancer is the most prevalent type of cancer worldwide and warrants that a greater market segment be available to serve the large patient population. The demand for screening and diagnostic technologies is expected to increase in breast cancer disorders, which will see a significant rise in their incidence.
Function Insights
Next-generation cancer diagnostics space can be broadly divided into risk analysis and tumor screening, prognostic-based diagnosis, therapeutic monitoring & companion diagnostics.
Market for next-generation cancer diagnostics worldwide, according to application, 2015 (USD million)
Prognostic diagnostics is expected to grow significantly over the forecast period. This is due to the fact the prognosis for cancer varies from one patient to another. It plays an important role in the design of cancer therapies and protocols.
Regional Insights
North America was the dominant market for next-generation oncology diagnostics, accounting for more than 40% of its revenue. Market growth is expected to be boosted by the launch of government initiatives like the "80% by 2018," movement for the detection of colon cancer. Over 170 organizations, including government health departments and medical professional societies, as well as cancer coalitions and health departments, are part of this movement. They have all committed to achieving the common goal of screening for oncology disorders at 80% by 2018.
Asia Pacific is expected be the fastest-growing region in this sector, and it is expected to grow at an impressive rate. A large untapped market base that has seen technological advances in healthcare research over recent years is one factor accounting for the faster growth. The market potential will be further enhanced by significant investments in healthcare research and economic development of these regions over the forecast period.
Competitive Insights
Cepheid, Koninklijke Philips N.V., F. Hoffmann-La Roche Ltd., Novartis AG, Abbott; Thermo Fisher Scientific, Inc., Opko Health, Inc., Myriad Genetics, Inc., Agilent Technologies, GE Healthcare, PerkinElmer, Inc., Genomic Health, Inc., Illumina, Inc., Hologic, Inc., Almac Group, Janssen Global Services, LLC, and Sysmex Corporation
Participants in the market are involved in implementing geographic expansion strategies, providing clinical testing facilities in under-tapped areas. Participants are also involved in gaining reimbursement coverage that will increase patient access to precision medicine. In the United States, Medicare began the reimbursement process for Oncotype Dx (a test for prostate cancer) in October 2015.
Report Scope
Attribute |
More Details |
Estimation base year |
2015 |
Actual estimates/Historical data |
2013 - 2015. |
Forecast period |
2016 - 2024 |
Representation of the market |
From 2016 to 2024, revenue in USD million and CAGR |
Regional scope |
North America, Europe and Asia Pacific, Latin America, Middle East, & Africa |
Report coverage |
Forecast revenue, company share, competitive landscape and growth factors and trends |
15% off customization scope (equivalent of 5 analyst working days). |
We will customize the report to provide you with specific market information that is not included in the current report. |
The Report Covers Certain Segments
This report predicts revenue growth at the global, regional and country level. It also provides analysis of industry trends and potential opportunities for each sub-segment from 2013 through 2024. Grand View Research has divided the market for next-generation cancer diagnostics on the basis technology, applications, function and cancer type.
-
Technology Outlook (Revenue USD Million; 2013-2024).
-
Next-Generation Sequencing
-
Multiplexing & qPCR
-
Lab-on-a-chip (LOAC), & Reverse Transcriptase PCR (RTPCR).
-
Protein Microarrays
-
DNA Microarrays
-
-
App Outlook (Revenue USD Million; 2013-2024).
-
Biomarker Development
-
CTC Analysis
-
Proteomic Analysis
-
Epigenetic Analysis
-
Genetic Analysis
-
-
The Cancer Type Outlook (Revenue USD Million; 2013-2024).
-
Lung Cancer
-
Breast Cancer
-
Colorectal Cancer
-
Cervical Cancer
-
Other
-
-
Function Outlook (Revenue USD Million; 2013-2024).
-
Therapeutic Monitoring
-
Companion Diagnostics
-
Prognostics
-
Cancer screening
-
Risk Analysis
-
-
Regional Outlook (Revenue USD Million; 2013-2024).
-
North America
-
The U.S.
-
Canada
-
-
Europe
-
Germany
-
The U.K.
-
-
Asia Pacific
-
Japan
-
China
-
-
Latin America
-
Brazil
-
-
Middle East & Africa
-
South Africa
-
-
Up Market Research published a new report titled “Next Generation Cancer Diagnostics Market research report which is segmented by Technology (LOAC & RT-PCR, NGS), by Application (Biomarker, CTC), by Cancer Type (Breast, Lung), By Players/Companies Cepheid; Koninklijke Philips NV; F Hoffmann-La Roche Ltd; Qiagen; Novartis AG; Abbott; Thermo Fisher Scientific, Inc; Agilent Technologies; GE Healthcare; PerkinElmer, Inc; Genomic Health, Inc; Opko Health, Inc; Hologic, Inc; Myriad Genetics, Inc; Illumina, LLC; and Sysmex Corporation, Inc; Almac Group; Janssen Global Services”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.
Report Scope
Report Attributes | Report Details |
Report Title | Next Generation Cancer Diagnostics Market Research Report |
By Technology | LOAC & RT-PCR, NGS |
By Application | Biomarker, CTC |
By Cancer Type | Breast, Lung |
By Companies | Cepheid; Koninklijke Philips NV; F Hoffmann-La Roche Ltd; Qiagen; Novartis AG; Abbott; Thermo Fisher Scientific, Inc; Agilent Technologies; GE Healthcare; PerkinElmer, Inc; Genomic Health, Inc; Opko Health, Inc; Hologic, Inc; Myriad Genetics, Inc; Illumina, LLC; and Sysmex Corporation, Inc; Almac Group; Janssen Global Services |
Regions Covered | North America, Europe, APAC, Latin America, MEA |
Base Year | 2020 |
Historical Year | 2018 to 2019 (Data from 2010 can be provided as per availability) |
Forecast Year | 2028 |
Number of Pages | 200 |
Number of Tables & Figures | 140 |
Customization Available | Yes, the report can be customized as per your need. |
The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.
Global Next Generation Cancer Diagnostics Market Report Segments:
The market is segmented by Technology (LOAC & RT-PCR, NGS), by Application (Biomarker, CTC), by Cancer Type (Breast, Lung).
Next Generation Cancer Diagnostics Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.
Key Benefits for Industry Participants & Stakeholders:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Next Generation Cancer Diagnostics Market
Overview of the regional outlook of the Next Generation Cancer Diagnostics Market:
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.
Highlights of The Next Generation Cancer Diagnostics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of Next Generation Cancer Diagnostics Market.
- Historical data and forecast.
- Estimations for the forecast period 2028.
- Developments and trends in the market.
1. LOAC & RT-PCR
2. NGS
7. By Application:1. Biomarker
2. CTC
8. By Cancer Type:1. Breast
2. Lung
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Next Generation Cancer Diagnostics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
Reasons to Purchase the Next Generation Cancer Diagnostics Market Report:
- The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
- Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
- Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
- The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
- Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Next Generation Cancer Diagnostics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Next Generation Cancer Diagnostics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Next Generation Cancer Diagnostics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Next Generation Cancer Diagnostics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Next Generation Cancer Diagnostics Market Size & Forecast, 2018-2028
4.5.1 Next Generation Cancer Diagnostics Market Size and Y-o-Y Growth
4.5.2 Next Generation Cancer Diagnostics Market Absolute $ Opportunity
Chapter 5 Global Next Generation Cancer Diagnostics Market Analysis and Forecast by Technology
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Technology
5.1.2 Basis Point Share (BPS) Analysis by Technology
5.1.3 Absolute $ Opportunity Assessment by Technology
5.2 Next Generation Cancer Diagnostics Market Size Forecast by Technology
5.2.1 LOAC & RT-PCR
5.2.2 NGS
5.3 Market Attractiveness Analysis by Technology
Chapter 6 Global Next Generation Cancer Diagnostics Market Analysis and Forecast by Application
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Application
6.1.2 Basis Point Share (BPS) Analysis by Application
6.1.3 Absolute $ Opportunity Assessment by Application
6.2 Next Generation Cancer Diagnostics Market Size Forecast by Application
6.2.1 Biomarker
6.2.2 CTC
6.3 Market Attractiveness Analysis by Application
Chapter 7 Global Next Generation Cancer Diagnostics Market Analysis and Forecast by Cancer Type
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Cancer Type
7.1.2 Basis Point Share (BPS) Analysis by Cancer Type
7.1.3 Absolute $ Opportunity Assessment by Cancer Type
7.2 Next Generation Cancer Diagnostics Market Size Forecast by Cancer Type
7.2.1 Breast
7.2.2 Lung
7.3 Market Attractiveness Analysis by Cancer Type
Chapter 8 Global Next Generation Cancer Diagnostics Market Analysis and Forecast by Region
8.1 Introduction
8.1.1 Key Market Trends & Growth Opportunities by Region
8.1.2 Basis Point Share (BPS) Analysis by Region
8.1.3 Absolute $ Opportunity Assessment by Region
8.2 Next Generation Cancer Diagnostics Market Size Forecast by Region
8.2.1 North America
8.2.2 Europe
8.2.3 Asia Pacific
8.2.4 Latin America
8.2.5 Middle East & Africa (MEA)
8.3 Market Attractiveness Analysis by Region
Chapter 9 Coronavirus Disease (COVID-19) Impact
9.1 Introduction
9.2 Current & Future Impact Analysis
9.3 Economic Impact Analysis
9.4 Government Policies
9.5 Investment Scenario
Chapter 10 North America Next Generation Cancer Diagnostics Analysis and Forecast
10.1 Introduction
10.2 North America Next Generation Cancer Diagnostics Market Size Forecast by Country
10.2.1 U.S.
10.2.2 Canada
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 North America Next Generation Cancer Diagnostics Market Size Forecast by Technology
10.6.1 LOAC & RT-PCR
10.6.2 NGS
10.7 Basis Point Share (BPS) Analysis by Technology
10.8 Absolute $ Opportunity Assessment by Technology
10.9 Market Attractiveness Analysis by Technology
10.10 North America Next Generation Cancer Diagnostics Market Size Forecast by Application
10.10.1 Biomarker
10.10.2 CTC
10.11 Basis Point Share (BPS) Analysis by Application
10.12 Absolute $ Opportunity Assessment by Application
10.13 Market Attractiveness Analysis by Application
10.14 North America Next Generation Cancer Diagnostics Market Size Forecast by Cancer Type
10.14.1 Breast
10.14.2 Lung
10.15 Basis Point Share (BPS) Analysis by Cancer Type
10.16 Absolute $ Opportunity Assessment by Cancer Type
10.17 Market Attractiveness Analysis by Cancer Type
Chapter 11 Europe Next Generation Cancer Diagnostics Analysis and Forecast
11.1 Introduction
11.2 Europe Next Generation Cancer Diagnostics Market Size Forecast by Country
11.2.1 Germany
11.2.2 France
11.2.3 Italy
11.2.4 U.K.
11.2.5 Spain
11.2.6 Russia
11.2.7 Rest of Europe
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Europe Next Generation Cancer Diagnostics Market Size Forecast by Technology
11.6.1 LOAC & RT-PCR
11.6.2 NGS
11.7 Basis Point Share (BPS) Analysis by Technology
11.8 Absolute $ Opportunity Assessment by Technology
11.9 Market Attractiveness Analysis by Technology
11.10 Europe Next Generation Cancer Diagnostics Market Size Forecast by Application
11.10.1 Biomarker
11.10.2 CTC
11.11 Basis Point Share (BPS) Analysis by Application
11.12 Absolute $ Opportunity Assessment by Application
11.13 Market Attractiveness Analysis by Application
11.14 Europe Next Generation Cancer Diagnostics Market Size Forecast by Cancer Type
11.14.1 Breast
11.14.2 Lung
11.15 Basis Point Share (BPS) Analysis by Cancer Type
11.16 Absolute $ Opportunity Assessment by Cancer Type
11.17 Market Attractiveness Analysis by Cancer Type
Chapter 12 Asia Pacific Next Generation Cancer Diagnostics Analysis and Forecast
12.1 Introduction
12.2 Asia Pacific Next Generation Cancer Diagnostics Market Size Forecast by Country
12.2.1 China
12.2.2 Japan
12.2.3 South Korea
12.2.4 India
12.2.5 Australia
12.2.6 South East Asia (SEA)
12.2.7 Rest of Asia Pacific (APAC)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Asia Pacific Next Generation Cancer Diagnostics Market Size Forecast by Technology
12.6.1 LOAC & RT-PCR
12.6.2 NGS
12.7 Basis Point Share (BPS) Analysis by Technology
12.8 Absolute $ Opportunity Assessment by Technology
12.9 Market Attractiveness Analysis by Technology
12.10 Asia Pacific Next Generation Cancer Diagnostics Market Size Forecast by Application
12.10.1 Biomarker
12.10.2 CTC
12.11 Basis Point Share (BPS) Analysis by Application
12.12 Absolute $ Opportunity Assessment by Application
12.13 Market Attractiveness Analysis by Application
12.14 Asia Pacific Next Generation Cancer Diagnostics Market Size Forecast by Cancer Type
12.14.1 Breast
12.14.2 Lung
12.15 Basis Point Share (BPS) Analysis by Cancer Type
12.16 Absolute $ Opportunity Assessment by Cancer Type
12.17 Market Attractiveness Analysis by Cancer Type
Chapter 13 Latin America Next Generation Cancer Diagnostics Analysis and Forecast
13.1 Introduction
13.2 Latin America Next Generation Cancer Diagnostics Market Size Forecast by Country
13.2.1 Brazil
13.2.2 Mexico
13.2.3 Rest of Latin America (LATAM)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Latin America Next Generation Cancer Diagnostics Market Size Forecast by Technology
13.6.1 LOAC & RT-PCR
13.6.2 NGS
13.7 Basis Point Share (BPS) Analysis by Technology
13.8 Absolute $ Opportunity Assessment by Technology
13.9 Market Attractiveness Analysis by Technology
13.10 Latin America Next Generation Cancer Diagnostics Market Size Forecast by Application
13.10.1 Biomarker
13.10.2 CTC
13.11 Basis Point Share (BPS) Analysis by Application
13.12 Absolute $ Opportunity Assessment by Application
13.13 Market Attractiveness Analysis by Application
13.14 Latin America Next Generation Cancer Diagnostics Market Size Forecast by Cancer Type
13.14.1 Breast
13.14.2 Lung
13.15 Basis Point Share (BPS) Analysis by Cancer Type
13.16 Absolute $ Opportunity Assessment by Cancer Type
13.17 Market Attractiveness Analysis by Cancer Type
Chapter 14 Middle East & Africa (MEA) Next Generation Cancer Diagnostics Analysis and Forecast
14.1 Introduction
14.2 Middle East & Africa (MEA) Next Generation Cancer Diagnostics Market Size Forecast by Country
14.2.1 Saudi Arabia
14.2.2 South Africa
14.2.3 UAE
14.2.4 Rest of Middle East & Africa (MEA)
14.3 Basis Point Share (BPS) Analysis by Country
14.4 Absolute $ Opportunity Assessment by Country
14.5 Market Attractiveness Analysis by Country
14.6 Middle East & Africa (MEA) Next Generation Cancer Diagnostics Market Size Forecast by Technology
14.6.1 LOAC & RT-PCR
14.6.2 NGS
14.7 Basis Point Share (BPS) Analysis by Technology
14.8 Absolute $ Opportunity Assessment by Technology
14.9 Market Attractiveness Analysis by Technology
14.10 Middle East & Africa (MEA) Next Generation Cancer Diagnostics Market Size Forecast by Application
14.10.1 Biomarker
14.10.2 CTC
14.11 Basis Point Share (BPS) Analysis by Application
14.12 Absolute $ Opportunity Assessment by Application
14.13 Market Attractiveness Analysis by Application
14.14 Middle East & Africa (MEA) Next Generation Cancer Diagnostics Market Size Forecast by Cancer Type
14.14.1 Breast
14.14.2 Lung
14.15 Basis Point Share (BPS) Analysis by Cancer Type
14.16 Absolute $ Opportunity Assessment by Cancer Type
14.17 Market Attractiveness Analysis by Cancer Type
Chapter 15 Competition Landscape
15.1 Next Generation Cancer Diagnostics Market: Competitive Dashboard
15.2 Global Next Generation Cancer Diagnostics Market: Market Share Analysis, 2019
15.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
15.3.1 Cepheid; Koninklijke Philips NV; F Hoffmann-La Roche Ltd; Qiagen; Novartis AG; Abbott; Thermo Fisher Scientific
15.3.2 Inc; Agilent Technologies; GE Healthcare; PerkinElmer
15.3.3 Inc; Genomic Health
15.3.4 Inc; Opko Health
15.3.5 Inc; Hologic
15.3.6 Inc; Myriad Genetics
15.3.7 Inc; Illumina
15.3.8 LLC; and Sysmex Corporation
15.3.9 Inc; Almac Group; Janssen Global Services